The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
520
LEAN, OVERWEIGHT AND OBESE MASLD PATIENTS HAVE SIMILAR AMOUNTS OF FIBROSIS THAT IS ASSOCIATED WITH POLYGENIC RISK
Date
May 19, 2024
Explore related products in the following collection:
INTRODUCTION. MAESTRO-NASH (NCT03900429) is an ongoing 54-month, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy of resmetirom in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis…